prog - PROG STOCK NEWS

Progenity, Inc. (Nasdaq: PROG) will report its first quarter financial results on May 10, 2022, post-market close. The webcast and conference call will commence at 4:30 p.m. Eastern time. The company has recently completed its legal name change to Biora Therapeutics, which will officially be launched during the earnings call. The NASDAQ ticker will change from 'PROG' to 'BIOR' on the same day. Progenity specializes in gastrointestinal health and oral biotherapeutics, focusing on targeted drug delivery and diagnostic solutions.

Progenity Appoints New SVP

Progenity (Nasdaq: PROG) has appointed Paul Shabram as Senior Vice President of Technical Operations. With over 30 years in biotech, Shabram has a history of leading successful development programs. CEO Adi Mohanty expressed confidence in Shabram's leadership amidst plans to ramp up manufacturing and clinical trials following strong preclinical data. Progenity also announced a stock option and restricted stock units as inducement awards for Shabram, valuing $150,000 each, with grants scheduled for May 2022.

Progenity, Inc. will change its name to Biora Therapeutics, Inc. in the second quarter of 2022, reflecting its focus on oral delivery of biotherapeutics. The name change coincides with the company's Q1 earnings call in May, and the NASDAQ ticker symbol will change from PROG to BIOR. The legal name change is set for around April 26, 2022, pending regulatory requirements. CEO Adi Mohanty emphasized the strategic transformation aimed at enhancing drug delivery methods for gastrointestinal health.

Progenity, a biotechnology company (Nasdaq: PROG), announced the acceptance of two abstracts that will present preclinical data on their systemic therapeutics delivery system at the Controlled Release Society (CRS) 2022 Annual Meeting, scheduled for July 11-15, 2022, in Montreal, Canada. The abstracts cover the development and performance assessment of an oral biotherapeutic delivery system. They will be published by CRS before the conference and available on Progenity’s website post-event.

Progenity, a biotechnology company focused on oral delivery biotherapeutics, provided updates on its transformation and fourth-quarter financial results for 2021. The company generated $7.7 million in revenue, mainly from discontinued operations, while net loss reached $92.9 million. Operating expenses decreased to $20.6 million. Notably, Progenity initiated a clinical device performance study for ulcerative colitis and completed a significant sale, enhancing its liquidity. The company aims to complete its transformation by mid-2022, with a focus on its targeted therapeutics program to address unmet needs in GI disorders.

Progenity, Inc. (Nasdaq: PROG) announced plans to report its financial results for Q4 and the full year ending December 31, 2021, on March 28, 2022, after market close. The company will conduct a conference call at 4:30 p.m. Eastern to discuss the results and provide a corporate update. Interested parties can access the call via phone or a live webcast on Progenity's website, with a replay available for 60 days.

Progenity (Nasdaq: PROG) has reported progress in its clinical device performance study for its Drug Delivery System (DDS) capsule aimed at treating ulcerative colitis. The initial study in healthy volunteers demonstrated the device's safety and ability to accurately localize and release a therapeutic payload in the colon. Following this success, Progenity is now recruiting patients with active ulcerative colitis for further evaluation of the DDS performance. The goal is to prepare for a therapeutic intervention trial for the PGN-600 program.

Progenity, Inc. (Nasdaq: PROG) announced the acceptance of three abstracts for presentation at Digestive Disease Week® (DDW), taking place May 21-24, 2022. These abstracts highlight advancements in the treatment of inflammatory bowel disease (IBD) and microbiome sampling. The presentations include Tofacitinib tissue exposure, cytokine profiles during anti-TNF treatment, and a novel method for microbiome specimen collection. These developments are significant for enhancing gastrointestinal health and improving patient outcomes through precise diagnostic methods.

Progenity, Inc. (Nasdaq: PROG) announced significant findings on therapeutic exposure for ulcerative colitis during the ECCO Congress. Key presentations highlighted the role of interleukin-6 as a potential target for combination therapy and established a link between mucosal exposure and treatment outcomes with tofacitinib.

The company's Drug Delivery System (DDS) aims to enhance therapeutic delivery to affected tissues while reducing systemic toxicity. Progenity is also advancing the PGN-600 program, targeting a Phase 1 clinical trial in late 2022.